Evofem Biosciences, Inc. (EVFM)
OTCMKTS
· Delayed Price · Currency is USD
0.0095
-0.0005 (-5.00%)
Dec 5, 2025, 3:50 PM EST
Evofem Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 17.73 | 19.36 | 18.22 | 16.84 | 8.24 | 0.45 | Upgrade
|
| Revenue Growth (YoY) | 3.67% | 6.29% | 8.20% | 104.23% | 1748.43% | - | Upgrade
|
| Cost of Revenue | 3.54 | 3.83 | 6.51 | 4.42 | 4.05 | 0.47 | Upgrade
|
| Gross Profit | 14.19 | 15.53 | 11.71 | 12.42 | 4.19 | -0.02 | Upgrade
|
| Selling, General & Admin | 19.54 | 20.74 | 26.74 | 71.72 | 138.36 | 86.97 | Upgrade
|
| Research & Development | -3.17 | 1.84 | 2.81 | 24.82 | 32.63 | 16.64 | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.73 | 0.62 | - | - | - | - | Upgrade
|
| Operating Expenses | 17.1 | 23.21 | 29.55 | 96.55 | 170.99 | 103.6 | Upgrade
|
| Operating Income | -2.91 | -7.68 | -17.85 | -84.12 | -166.8 | -103.62 | Upgrade
|
| Interest Expense | -2.58 | -2.58 | -2.63 | -2.09 | -4.73 | -2.08 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | 0.03 | 0.09 | 0.02 | 0.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.9 | 0.4 | -1.9 | 33.96 | -33.66 | -36.77 | Upgrade
|
| EBT Excluding Unusual Items | -7.36 | -9.84 | -22.34 | -52.17 | -205.18 | -142.31 | Upgrade
|
| Other Unusual Items | 1.93 | 0.98 | 75.34 | -24.49 | - | - | Upgrade
|
| Pretax Income | -5.43 | -8.86 | 53 | -76.65 | -205.18 | -142.31 | Upgrade
|
| Income Tax Expense | 0 | - | 0.02 | 0.04 | 0.02 | 0 | Upgrade
|
| Earnings From Continuing Operations | -5.43 | -8.86 | 52.98 | -76.7 | -205.19 | -142.31 | Upgrade
|
| Net Income | -5.43 | -8.86 | 52.98 | -76.7 | -205.19 | -142.31 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.12 | 0.11 | 2.98 | 1.32 | 1.05 | - | Upgrade
|
| Net Income to Common | -5.56 | -8.97 | 50 | -78.01 | -206.24 | -142.31 | Upgrade
|
| Shares Outstanding (Basic) | 114 | 75 | 5 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 75 | 984 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 120.19% | -92.36% | 211082.03% | 567.40% | 94.93% | 66.94% | Upgrade
|
| EPS (Basic) | -0.05 | -0.12 | 10.36 | -167.42 | -2953.95 | -3973.23 | Upgrade
|
| EPS (Diluted) | -0.05 | -0.12 | 0.05 | -167.42 | -2953.95 | -3975.00 | Upgrade
|
| Free Cash Flow | -4.43 | -3.9 | -8.97 | -70.75 | -149.61 | -107.08 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.05 | -0.01 | -151.84 | -2142.80 | -2989.73 | Upgrade
|
| Gross Margin | 80.05% | 80.20% | 64.25% | 73.78% | 50.81% | -4.93% | Upgrade
|
| Operating Margin | -16.41% | -39.64% | -97.96% | -499.64% | -2023.30% | -23234.08% | Upgrade
|
| Profit Margin | -31.34% | -46.30% | 274.43% | -463.35% | -2501.69% | -31907.85% | Upgrade
|
| Free Cash Flow Margin | -25.01% | -20.14% | -49.25% | -420.21% | -1814.73% | -24009.64% | Upgrade
|
| EBITDA | -2.16 | -7.03 | -17.37 | -83.11 | -165.78 | -103.32 | Upgrade
|
| EBITDA Margin | -12.20% | -36.29% | -95.34% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.75 | 0.65 | 0.48 | 1.02 | 1.02 | 0.3 | Upgrade
|
| EBIT | -2.91 | -7.68 | -17.85 | -84.12 | -166.8 | -103.62 | Upgrade
|
| EBIT Margin | -16.41% | -39.64% | -97.96% | - | - | - | Upgrade
|
| Effective Tax Rate | - | - | 0.03% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.